Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

Source: 2021 Global Conference Coverage: An Update on the Clinical Development Across Gynecologic Malignancies*
The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic

In this podcast episode, listen to Ursula Matulonis, MD, and Jubilee Brown, MD, discuss new data for gynecological cancers presented at the virtual SGO 2021 meeting, including immunotherapy-based combinations for endometrial cancer and PARP inhibitors for BRCA-mutated ovarian cancers.

This podcast is intended for clinicians practicing medicine outside of the United States.

Jubilee Brown, MD
Ursula Matulonis, MD
Released: April 7, 2021

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:

  • Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer
  • Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer
  • 5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer
  • Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer
  • OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer

Presenters:

Jubilee Brown, MD
Professor and Director of Gynecologic Oncology
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

person default Nicole Concin, MD, PhD Released: November 23, 2021

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on individualizing care for women with cervical cancer based on current and emerging clinical data, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 22, 2021 Expired: November 21, 2022

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on patient underrepresented and minority women enrollment on clinical trials for cervical cancer, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 16, 2021 Expired: November 15, 2022

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue